Trials / Completed
CompletedNCT04641143
Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder
A Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 456 (actual)
- Sponsor
- Biohaven Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The study's purpose is to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compulsive Disorder (OCD)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Troriluzole | Troriluzole - 2 100mg capsules QD for the first two weeks. |
| DRUG | Placebo | Matching placebo - 2 140mg capsules QD from week two through week ten. |
Timeline
- Start date
- 2020-12-22
- Primary completion
- 2025-10-27
- Completion
- 2025-10-27
- First posted
- 2020-11-23
- Last updated
- 2026-01-07
Locations
73 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04641143. Inclusion in this directory is not an endorsement.